Patient Registry Software Market worth $3.99 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the global patient registry software market will grow from USD 2.47 billion in 2026 to USD 3.99 billion by 2031, a 10.0% CAGR. North America held 48.4% of the market in 2025, while Asia Pacific is expected to post the fastest forecast-period growth; cloud-based platforms held the largest deployment-model share and disease registries are projected to grow at a 10.3% CAGR. Growth drivers include demand for real-world evidence and digital health tools, while cost, interoperability, staffing, and privacy concerns may constrain adoption.

Analysis

The investable signal is not the headline market-growth estimate; it is whether registry software becomes a paid data-collection layer for clinical research and real-world evidence, rather than a feature bundled into EHR, analytics, or clinical-trial platforms. If bundling wins, standalone vendors may see adoption without pricing power. Conversely, interoperable platforms that reduce manual abstraction and demonstrate measurable recruitment or outcomes value could capture higher-value workflows. IQVIA and Dassault Systèmes’ Medidata have strategic adjacency through research workflows; Elekta’s oncology registry integration could strengthen its software ecosystem. But the release supplies no company-level revenue exposure, contract economics, or independent adoption data, so these are hypotheses—not earnings upgrades. For diversified IBM and Oracle, the addressable category is unlikely to matter absent evidence of material segment contribution. Health Catalyst’s adjacent acquisitions likewise do not establish registry revenue acceleration.

Near term, expect little durable stock impact: the source is a market-research promotion, and a top-down forecast does not prove budgets, implementation conversion, or vendor share. Over 1–3 months, watch named vendors’ earnings commentary for registry bookings, recurring software revenue, implementation timelines, and customer retention; over 6–18 months, interoperability, privacy requirements, and AI-assisted abstraction may decide economics. The contrarian risk is treating cloud adoption as pure vendor upside: migration costs, integration burden, and security exposure can delay deployments and favor incumbent platforms. Thesis weakens if vendors report slower healthcare software growth, extended implementations, or no measurable RWE/clinical-trial demand. No immediate directional trade is justified on this release alone.

Key Decisions for Investors

• Do not buy the listed names on the market-size estimate alone; treat it as a low-conviction sector signal, not company-specific guidance.
• Put IQV, DSY, and EKTA.B on a 1–3 month monitoring list; require reported registry/RWE bookings or quantified cross-sell before assigning incremental earnings value. Verify registry revenue and segment exposure, which the article does not provide.
• For HCAT, distinguish adjacent patient-engagement and workflow acquisitions from direct registry monetization; reassess only with evidence of cross-sell, retention, and implementation economics.
• Falsification/watch item: reduce the growth thesis if upcoming guidance or disclosures show slowing healthcare software demand, longer deployment cycles, weak customer conversion, or rising security/interoperability costs.